Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

British Journal of Haematology

Volumn 163, Issue 4, 2013, Pages 478-486

  Kaufman, Jonathan L ^a   Niesvizky, Ruben ^b   Stadtmauer, Edward A ^c   Chanan Khan, Asher ^d,g   Siegel, David ^e   Horne, Heather ^f   Wegener, William A ^f   Goldenberg, David M ^f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f IMMUNOMEDICS INC   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Antibody; CD74; Milatuzumab; Multiple myeloma; Phase 1 clinical trial

Indexed keywords

ANTIBIOTIC AGENT; CD74 ANTIGEN; INFUSION FLUID; MILATUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; B LYMPHOCYTE; BACKACHE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL MENINGITIS; BACTERIAL SINUSITIS; BILIRUBIN BLOOD LEVEL; BONE MARROW BIOPSY; BRADYCARDIA; CANCER GROWTH; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FALLING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; LEUKOCYTE; MALE; MAXIMUM TOLERATED DOSE; MONOCYTE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMACYTOMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SIDE EFFECT; SPINAL CORD COMPRESSION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIBODY; CD74; MILATUZUMAB; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE;

EID: 84886407377     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12565     Document Type: Article

References (37)

1. Alinari, L., Yu, B., Christian, B.A., Yan, F., Shin, J., Lapalombella, R., Hertlein, E., Lustberg, M.E., Quinion, C., Zhang, X., Lozanski, G., Muthusamy, N., Prætorius-Ibba, M., O'Connor, O.A., Goldenberg, D.M., Byrd, J.C., Blum, K.A. & Baiocchi, R.A. (2011) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood, 117, 4530-4541.
2. Anderson, K.C. (1997) Plasma cell tumors. In: Cancer Medicine, 4th edn. (eds by J.F. Holland, R.C. Bast Jr, D.L. Morton, E. Frei III, D.W. Kufe & R.R. Weichselbaum), pp. 2809-2828. Williams & Wilkins, Baltimore.
3. Barlogie, B., Shaugnessy, J., Munshi, N. & Epstein, J. (2001) Plasma cell myeloma. In: Williams Hematology, 6th edn (eds by E. Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps, U. Seligsohn), pp. 1279-1304. McGraw Hill, New York.
4. Binsky, I., Haran, M., Starlets, D., Gore, Y., Lantner, F., Harpaz, N., Leng, L., Goldenberg, D.M., Shvidel, L., Berrebi, A., Bucala, R. & Shachar, I. (2007) IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proceedings of the National Academy of Sciences of the United States of America, 104, 13408-13413.
5. Binsky, I., Lantner, F., Grabovsky, V., Harpaz, N., Shvidel, L., Berrebi, A., Goldenberg, D.M., Leng, L., Bucala, R., Alon, R., Haran, M. & Shachar, I. (2010) Tap63 regulates VSA-4 expression and CLL cell migration to the BM in a CD74 dependent manner. The Journal of Immunology, 184, 4761-4769.
6. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoetic stem cell transplantion. British Journal of Haematology, 102, 1115-1123.
7. Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. & Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 6606-6611.
8. Cresswell, P. (1994) Assembly, transport, and function of MHC class II molecules. Annual Review of Immunology, 12, 259-293.
9. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska Miguel, A., San, J., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. Knight, R.D. & the Multiple Myeloma (010) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 357, 2123-2132.
10. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
11. Durie, B.G.M. & Salmon, S.E. (1977) Muliple myeloma, macroglobulinemia and monoclonal gammopathies. In: Recent Advances in Hematology (eds by A.V. Hofbrand, M.C. Brain, J. Hirsh), pp. 243-261. Churchill Livingstone, Edinburgh.
12. Durie, B.G., Kyle, R.A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., Child, J.A., Comenzo, R., Djulbegovic, B., Fantl, D., Gahrton, G., Harousseau, J.L., Hungria, V., Joshua, D., Ludwig, H., Mehta, J., Morales, A.R., Morgan, G., Nouel, A., Oken, M., Powles, R., Roodman, D., San Miguel, J., Shimizu, K., Singhal, S., Sirohi, B., Sonneveld, P., Tricot, G. Van Ness, B. & the Scientific Advisors of the International Myeloma Foundation (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 4, 379-398.
13. Grogan, T.M. & Spier, C.M. (2001) B-cell immunoproliferative disorders, including multiple myeloma and amyloidosis. In: Neoplastic Hematopathology, 2nd edn (ed. by D.M. Knowles), pp. 1557-1587. Lippincott Williams & Wilkins, Philadelphia.
14. Gupta, P., Goldenberg, D.M., Rossi, E.A., Cardillo, T.M., Byrd, J.C., Muthusamy, N., Furman, R.R. & Chang, C.H. (2012) Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood, 119, 3767-3778.
15. Hertlein, E., Triantafillou, G., Sass, E.J., Hessler, J.D., Zhang, X., Jarjoura, D., Lucas, D.M., Muthusamy, N., Goldenberg, D.M., Lee, R.J. & Byrd, J.C. (2010) Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 116, 2554-2558.
16. Lonial, S., Vij, R., Harousseau, J.L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J.L., Leleu, X., Tsao, L.C., Westland, C., Singhal, A.K. & Jagannath, S. (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 30, 1953-1959.
17. Mao, Y., Triantafillou, G., Hertlein, E., Towns, W., Stefanovski, M., Mo, X., Jarjoura, D., Phelps, M., Marcucci, G., Lee, L.J., Goldenberg, D.M., Lee, R.J., Byrd, J.C. & Muthusamy, N. (2013) Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical Cancer Research, 19, 347-356.
18. Ong, G.L., Goldenberg, D.M., Hansen, H.J. & Mattes, M.J. (1999) Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology, 98, 296-302.
19. Orlowski, R.Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W. & Harousseau, J.L. (2007) Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 3892-3901.
20. Pawlak-Bycskowska, E.J., Hansen, H., Dion, A.S. & Goldenberg, D.M. (1989) Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Research, 49, 4568-4677.
21. Plesner, T., Lokhurst, H., Gimsing, P., Nahi, H., Lisby, S. & Richardson, P.G. (2012) Daratuzumab, a CD38 monoclonal antibody in patients with multiple myeloma: data from a dose-escalation phase I/II study. Blood (ASH Annual Meeting Abstracts), 120, 73.
22. Rajkumar, V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
23. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. & Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 352, 2487-2498.
24. Richardson, P.G., Lonial, S., Jakubowiak, A.J., Harousseau, J.L. & Anderson, K.C. (2011) Monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology, 154, 745-754.
25. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H., Richardson, P.G. & VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The New England Journal of Medicine, 359, 906-917.
26. Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S.V., Cardillo, T.M., Hansen, H.J., Horak, I.D., Griffiths, G.L. & Goldenberg, D.M. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clinical Cancer Research, 11, 5257-5264.
27. Siegel, R., Naishadham, D. & Jemal, A. (2012) Cancer statistics. CA: A Cancer Journal for Clinicians, 62, 10-29.
28. Starlets, D., Gore, Y., Binsky, I., Haran, M., Harpaz, N., Shvidel, L., Becker-Herman, S., Berrebi, A. & Shachar, I. (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood, 107, 4807-4816.
29. Stein, R., Qu, Z., Cardillo, T.M., Chen, S., Rosario, A., Horak, I.D., Hansen, H.J. & Goldenberg, D.M. (2004) Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood, 104, 3705-3711.
30. Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.-H., Burton, J., Govindan, S. & Goldenberg, D.M. (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research, 13, 5556s-5563s.
31. Stein, R., Smith, M.R., Chen, S., Zalath, M. & Goldenberg, D.M. (2009) Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clinical Cancer Research, 15, 2808-2817.
32. Tai, Y.-T. & Anderson, K.C. (2011) Antibody-based therapies in multiple myeloma. Bone Marrow Research, doi: 10.1155-2011-924058.
33. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. & the Multiple Myeloma (009) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England Journal of Medicine, 357, 2133-2142.
34. Yang, J. & Yi, Q. (2011) Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. American Journal of Blood Research, 1, 22-33.
35. Zaidi, A.A. & Vesole, D.H. (2001) Multiple myeloma: an old disease with new hope for the future. CA: A Cancer Journal for Clinicians, 51, 273-285.
36. Zojer, N., Kirchbacher, K., Vesely, M., Hübl, W. & Ludwig, H. (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukaemia & Lymphoma, 47, 1103-1109.
37. Zonder, J.A., Mohrbacher, A.F., Singhal, S., van Rhee, F., Bensinger, W.I., Ding, H., Fry, J., Afar, D.E. & Singhal, A.K. (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood, 120, 552-559.